income 1,136 1,219 1,284 5% 13% 3,395 3,774 11% Income tax expenses 219 241 257 6% 17% 666 753 13% Net profit for the period 901 942 991 5% 10% 2,690 2,920 9% Earning Per Share (Baht per share) 3.60 3.77

consider, allocate, and offer for sale at one time or divided into partly offering as appropriate. Because the said capital increase procedure does not comply with the regulations of the SEC, therefore, the

the table below. Revenue Consolidated financial statements for the period 2Q2016 2Q2017 Increase /(Decrease) Baht million Baht million Baht million % Industrial Water Sales 257.5 281.1 23.6 9.2 Raw

“Notifications on Acquisition or Disposal”), having the highest transaction value of 31.09 percent, calculated from the Consolidated Financial Statement of the Company for the period ending 30 June 2017, which is

Statement of the Company for the period ending 30 June 2017, which is the highest transaction value calculated by applying the third calculation basis, i.e. the Total Value of Consideration Basis

entered into the MRT Blue Line Concession Agreement with the Mass Rapid Transit Authority of Thailand ( the “MRTA”) on March 31, 2017 for the concession period of 33 years. The MRT Blue Line Project

Limited for the three months period ended March 31, 2019. And The Audited financial statement of BS Myco Biotech Company Limited for year ended December 31,2018. The calculation of transaction size (1) Book

% since there are no new projects completed in this quarter. However, the gross profit from sale increases 1.60%. At the same time, the income from rental property business and service and management

causing the offeror [CIS operator] of units of foreign collective investment scheme not to be able to submit the sale report as prescribed under Clause 9 to the SEC Office within the specified period, the

during the period. 3) Key Financial Performance Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Return on equity (ROE) 20.7% 20.3% 18.7% 15.8% 12.6% Return on asset (ROA) 8.1% 8.1% 7.3% 6.2% 5.2% Interest bearing